PGDx Inks Agreements With KingMed, Merck for Tissue-Based TMB Testing

Jan 03, 2019

NEW YORK (GenomeWeb) – Personal Genome Diagnostics has entered into a strategic collaboration with China's KingMed Diagnostics to use PGDx's Elio tissue complete assay to detect tumor mutational burden and other gene variants.

Separately, PGDx said it has also partnered with Merck as part of a phase II precision oncology study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

PGDx Inks Agreements With KingMed, Merck for Tissue-Based TMB Testing

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Guardant Health Prices $319.5M Public Stock Offering

Biocept Targets Pathologists, Naturopaths to Drive Liquid Biopsy Adoption

Sponsorships